Yu S - Search Results

1

HLA loss of heterozygosity-mediated discordant responses to immune checkpoint blockade in squamous cell lung cancer with renal metastasis.

Yu S, Zhao Z, Chen L, Gu T, Yu H, Tang H, Wang Q, Wu Y. Yu S, et al. Among authors: yu h. Immunotherapy. 2021 Feb;13(3):195-200. doi: 10.2217/imt-2020-0173. Epub 2020 Nov 26. Immunotherapy. 2021. PMID: 33238795

2

Next-generation Sequencing Identified a Novel WDPCP-ALK Fusion Sensitive to Crizotinib in Lung Adenocarcinoma.

He Z, Wu X, Ma S, Zhang C, Zhang Z, Wang S, Yu S, Wang Q. He Z, et al. Among authors: yu s. Clin Lung Cancer. 2019 Sep;20(5):e548-e551. doi: 10.1016/j.cllc.2019.06.001. Epub 2019 Jun 14. Clin Lung Cancer. 2019. PMID: 31281052 Free article. No abstract available.

3

Upregulation of IBSP Expression Predicts Poor Prognosis in Patients With Esophageal Squamous Cell Carcinoma.

Wang M, Liu B, Li D, Wu Y, Wu X, Jiao S, Xu C, Yu S, Wang S, Yang J, Li Y, Wang Q, Luo S, Tang H. Wang M, et al. Among authors: yu s. Front Oncol. 2019 Oct 25;9:1117. doi: 10.3389/fonc.2019.01117. eCollection 2019. Front Oncol. 2019. PMID: 31709184 Free PMC article.

4

Evolution of Lung Cancer in the Context of Immunotherapy.

Yu S, Wang R, Tang H, Wang L, Zhang Z, Yang S, Jiao S, Wu X, Wang S, Wang M, Xu C, Wang Q, Wu Y. Yu S, et al. Clin Med Insights Oncol. 2020 Dec 28;14:1179554920979697. doi: 10.1177/1179554920979697. eCollection 2020. Clin Med Insights Oncol. 2020. PMID: 33447125 Free PMC article. Review.

5

Case report: sequential use of almonertinib based on the EGFR exon 20 insertion mutation achieves long-term control for advanced non-small cell lung cancer patients.

Wang R, Yu S, Yu L, Zhao J, Jiao S, Wang Q, Wu Y. Wang R, et al. Among authors: yu l, yu s. Transl Cancer Res. 2022 Jun;11(6):1836-1843. doi: 10.21037/tcr-21-2728. Transl Cancer Res. 2022. PMID: 35836508 Free PMC article.

6

Riddle of the Sphinx: facts and evidence regarding the link between mental stress and tumor occurrence and development.

Wang R, Yu S, Yu L, Wang Q, Wu Y. Wang R, et al. Among authors: yu l, yu s. Chin Med J (Engl). 2022 Dec 20;135(24):2998-3000. doi: 10.1097/CM9.0000000000002129. Chin Med J (Engl). 2022. PMID: 36580651 Free PMC article. No abstract available.

7

Depression in breast cancer patients: Immunopathogenesis and immunotherapy.

Yu S, Li W, Tang L, Fan X, Yao S, Zhang X, Bi Z, Cheng H. Yu S, et al. Cancer Lett. 2022 Jun 28;536:215648. doi: 10.1016/j.canlet.2022.215648. Epub 2022 Mar 17. Cancer Lett. 2022. PMID: 35307487 Review.

8

Fear of cancer recurrence is related to the efficacy of immunotherapy and quality of life in patients with NSCLC during the COVID-19 pandemic in China.

Yin X, Cheng Y, Yao S, Wu J, Liu S, Li W, Yu S, Tang L, Jing Y, Pang L, Cheng H. Yin X, et al. Among authors: yu s. Am J Cancer Res. 2022 Aug 15;12(8):4040-4049. eCollection 2022. Am J Cancer Res. 2022. PMID: 36119842 Free PMC article.

9

The Managing Cancer and Living Meaningfully (CALM) Intervention Alleviates Chemotherapy-Related Cognitive Impairment in Patients with Breast Cancer by Modulating Pan-Immune-Inflammation Values.

Yao S, Ding K, Liu S, Zhang Q, Li W, Tang L, Yu S, Pang L, Yin X, Cheng H. Yao S, et al. Among authors: yu s. Integr Cancer Ther. 2022 Jan-Dec;21:15347354221140498. doi: 10.1177/15347354221140498. Integr Cancer Ther. 2022. PMID: 36419389 Free PMC article. Clinical Trial.

10

Psychological distress as risk factor for the efficacy of whole-brain radiotherapy in brain metastasis patients.

Li W, Gan C, Zuo H, Yin X, Jing Y, Pang L, Yu S, Tang L, Yao S, Cheng H. Li W, et al. Among authors: yu s. Future Oncol. 2023 Jan;19(1):49-60. doi: 10.2217/fon-2022-0690. Epub 2023 Jan 18. Future Oncol. 2023. PMID: 36651480

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

24,399 results

Search Page